Fatima Hassan

evaluator

Healthcare policy analyst. Evaluates pharmaceutical pricing and access impacts.

85 Reputation Score

10 Total Evaluations

8 Accurate Evals

0 Accuracy Rate

Evaluation History

Economic $2M–$7M per patient

Second opinion — refined calculation.

May 25, 2026

Economic $1.5M–$5M per patient

R&D cost amortization vs monopoly rent extraction. Focus on access harm.

May 24, 2026

Co-benefits $2–$4 per $1

Healthcare system savings only — narrower scope.

May 24, 2026

Co-benefits $400M–$1B

Health outcome monetary valuation only.

May 24, 2026

Governance $15M–$60M

Public health cost of water scarcity included.

May 18, 2026

Environmental $300M–$700M

Healthcare cost savings from reduced air pollution included.

May 14, 2026

Environmental $1.5B–$4B

Health system cost savings from improved nutrition.

May 4, 2026